Literature DB >> 24576774

High-sensitivity troponin level pre-catheterization predicts adverse cardiovascular outcomes after primary angioplasty for ST-elevation myocardial infarction.

Tom Kai Ming Wang1, Timothy A C Snow, Yang Chen, Hussam Rostom, Jonathon M White, James T Stewart, Mark W I Webster, Peter N Ruygrok, Timothy Watson, Harvey D White.   

Abstract

BACKGROUND: Cardiac troponins are the preferred biomarkers for diagnosing myocardial infarction (MI). High-sensitivity troponin T (hs-TnT) assays have increased sensitivity and enable more rapid diagnosis of infarction. We assessed the prognostic utility of admission hs-TnT to detect outcomes after primary angioplasty for ST-elevation/new left bundle branch block myocardial infarction (STEMI).
METHODS: Patients admitted to Auckland City Hospital for acute coronary catheterization with a diagnosis of STEMI between October 2010 and September 2011 were identified, and included if hs-TnT levels were measured at admission. Clinical characteristics and major adverse cardiovascular events (MACE: death, myocardial infarction and revascularization) at 30 days and 1 year were collected from national statistics and electronic medical records.
RESULTS: Median admission hs-TnT level in the 173 STEMI patients studied was 59 ng/L (interquartile range (IQR) 19-310). Incidences of MACE at 30 days and 1 year were 10% (n=17) and 18% (n=31), respectively. C-statistics and 95% confidence interval (CI) (95% CI) for hs-TnT on admission at detecting MACE at 30 days and 1 year were 0.800 (0.696-0.904) and 0.750 (0.655-0.845) respectively, with the optimal cut-point of 225 ng/L giving sensitivities/specificities of 76.5%/75.6% and 64.5%/78.2% respectively. Admission log(hs-TnT) independently predicted both MACE at 30 days with hazards ratio 5.16, 95% CI (2.25-11.9) and 1 year with hazards ratio 2.88, 95% CI (1.79-4.63), as did age and cardiogenic shock. Age, Maori or Pacific ethnicity and chronic respiratory disease were independent predictors of hs-TnT>225 ng/L.
CONCLUSION: Admission hs-TnT measured in primary angioplasty is strongly prognostic of MACE at 30 days and 1 year, even following adjustment for potential confounding variables.

Entities:  

Keywords:  ST-elevation myocardial infarction; Troponin; acute coronary syndrome; primary angioplasty; prognosis

Mesh:

Substances:

Year:  2014        PMID: 24576774     DOI: 10.1177/2048872614527006

Source DB:  PubMed          Journal:  Eur Heart J Acute Cardiovasc Care        ISSN: 2048-8726


  4 in total

1.  MicroRNA-208a: a Good Diagnostic Marker and a Predictor of no-Reflow in STEMI Patients Undergoing Primary Percutaneuos Coronary Intervention.

Authors:  Aboubakr Mohamed Salama; Wael Ali Khalil; Manar Al-Zaky; Somia Hassan Abdallah; Nader Talaat Kandil; Ahmed Abdelsabour; Ahmed Mohammed Shaker; Mesbah Taha Hasanein; Giovanni Battista Luciani; Hassan M E Azzazy
Journal:  J Cardiovasc Transl Res       Date:  2020-05-26       Impact factor: 4.132

2.  Peak troponin T in STEMI: a predictor of all-cause mortality and left ventricular function.

Authors:  Natasha Khullar; Anthony James Buckley; Cormac O'Connor; Abdalla Ibrahim; Alsamawal Ibrahim; Catriona Ahern; Ciara Cahill; Samer Arnous; Thomas John Kiernan
Journal:  Open Heart       Date:  2022-05

3.  Prognostic Value of New-Generation Troponins in ST-Segment-Elevation Myocardial Infarction in the Modern Era: The RUTI-STEMI Study.

Authors:  Germán Cediel; Ferran Rueda; Cosme García; Teresa Oliveras; Carlos Labata; Jordi Serra; Julio Núñez; Vicent Bodí; Marc Ferrer; Josep Lupón; Antoni Bayes-Genis
Journal:  J Am Heart Assoc       Date:  2017-12-23       Impact factor: 5.501

4.  Relationship Between Troponin on Presentation and In-Hospital Mortality in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

Authors:  Brett L Wanamaker; Milan M Seth; Devraj Sukul; Simon R Dixon; Deepak L Bhatt; Ryan D Madder; John S Rumsfeld; Hitinder S Gurm
Journal:  J Am Heart Assoc       Date:  2019-09-24       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.